

INTRODUCTION

Since 2004, the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia has had a strong influence on the regional response to the HIV epidemic. The process to monitor the Dublin Declaration has provided valuable data on what is being done by countries and where improvements in national programmes must be made to reduce the number of new infections and improve the quality of life for people living with HIV.

One of the major changes for 2018 reporting is the further harmonisation of UNAIDS/WHO and ECDC reporting processes. For this reporting round, EU/EEA countries will not be approached by UNAIDS/WHO with a separate request for data. Instead essential GAM indicators are included in the 2018 Dublin Declaration questionnaire for these countries and shared with UNAIDS/WHO following data collection. The 2018 GAM reporting guidance can be accessed [here](#) and is linked to where relevant within the survey.

For non-EU/EEA countries, UNAIDS/WHO will continue to approach them for data via the GAM reporting tool. They will receive a shortened 2018 Dublin Declaration Questionnaire with any GAM indicators removed to avoid duplication. This approach should considerably reduce the reporting burden on countries whilst ensuring that UNAIDS, WHO and ECDC are able to access the data that they need.

Another major change is the use of survey software to enable the questionnaire to be completed online. The benefit of this approach is that questions can be routed depending on responses, ensuring that countries aren't asked questions that aren't relevant to them - resulting in a shorter questionnaire and reduced reporting burden.

For this reporting round, we have maintained the focus on a single questionnaire that is submitted by government and civil society jointly. Key stakeholders from both sectors are strongly encouraged to work together to complete the questionnaire as accurately and transparently as possible. We have also maintained the 2016 questionnaire structure which aligns closely with the core components of national responses to HIV: strategic information, prevention, testing, treatment, continuum of care and spending.

The questionnaire must be filled out online but it can be downloaded as a pdf file so countries can review the questions prior to completing the online questionnaire. Please note that the pdf file contains all possible questions that countries could be asked, making it significantly longer than the online version. Please see the General instructions on the next page for additional information on completing the questionnaire.

You can download an pdf version of the questionnaire [here](#)

GENERAL INSTRUCTIONS

- 1) Each section of the online questionnaire can be saved and reopened via the link provided while it is being filled in. When you click save, you can close the survey and re-enter it via the same link on the landing page. After it has been saved, responses to individual questions can be changed and/or edited.
- 2) You can share the access code and link to the survey with any experts in your country you wish to assist you reporting specific data. Multiple people can use the same access code at the same time for different sections.
- 3) You must answer questions that are marked with a red asterisk (*). Questions without an asterisk only need to be answered if you have the data required.
- 4) On the final page of each section, you will be asked to review your answers for accuracy and upload any attachments you wish to submit alongside your answers before submitting it to ECDC.
- 5) If attachments are part of your submission, please use the following types of files: PDF, Word and Excel.
- 6) Once you click 'SUBMIT' you will no longer be able to access your answers, so please **do not click 'SUBMIT'** until you are completely satisfied with your responses.
- 7) Please provide the requested contact information in this section of the questionnaire. It is important to provide information for both primary and secondary contact people so ECDC knows who to consult if there are questions or clarifications related to your submission.
- 8) Please report the most current data that is available. You can specify the reporting period; it does not need to be based on a calendar year. If more recent data are available, you may choose to report that data. In all cases, please provide the date(s) associated with data submitted.
- 9) Several questions ask for the primary source of data. If multiple sources of data are used to track a specific issue, please report the primary or most important source of data.
- 10) In the text boxes included in the questionnaire, please provide complete but concise information. Additional information can be uploaded on the final page of each section.
- 11) English is the official working language of ECDC. If possible, please provide information in this language.

Q1.2 * Please select your country:

- Albania
- Andorra
- Armenia
- Austria
- Azerbaijan
- Belarus
- Belgium
- Bosnia and Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Georgia
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Israel
- Italy
- Kazakhstan
- Kosovo
- Kyrgyzstan
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Malta
- Monaco
- Montenegro
- Netherlands
- Norway
- Poland
- Portugal
- Republic of Moldova
- Romania
- Russian Federation

Q1.2 * Please select your country:

- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Tajikistan
- The former Yugoslav Republic of Macedonia
- Turkey
- Turkmenistan
- Ukraine
- United Kingdom
- Uzbekistan

The purpose of this page is to capture contact information for the key people with direct responsibility for completing this questionnaire. In the spaces provided below, please provide the requested details for the key government and civil society contacts. ECDC strongly recommends that government and civil society collaborate in responding to this questionnaire.

Primary Government Contact

Q1.3 * First Name:

Q1.4 * Surname:

Q1.5 * Job Title:

Q1.6 * Email Address:

Q1.7 Phone Number:

Secondary Government Contact

Q1.8 * First Name:

Q1.9 * Surname:

Q1.10 * Job Title:

Q1.11 * Email Address:

Q1.12 Phone Number:

Civil Society Contact

Q1.13 * Did representatives from civil society participate in completing this questionnaire? Yes No [Go to Q2.1](#)

Q1.14 * Please give details on the nature of involvement:

Q1.15 * First Name:

Q1.16 * Surname:

Q1.17 * Job Title:

Q1.18 * Email Address:

Q1.19 Phone Number:

STRATEGIC INFORMATION

* There are a range of key populations which are usually identified as being most affected by HIV at a European level. Using the list below, please rank the **three** key populations which are the main focus of your prevention, testing and treatment efforts from 1 to 3 (with 1 being most important and 3 being least important).

	1	2	3
Q2.1a Men who have sex with men	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q2.1b Migrants (persons born abroad)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q2.1c People who inject drugs	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q2.1d Prisoners	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q2.1e Sex workers	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q2.1f Trans people	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q2.1g Any other key population	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If relevant, please specify which other key population:

Q2.2 * Have you observed any decline in new HIV diagnoses in any key population, at a national or sub-national level, over the past two years?

Yes

No

Go to Q2.6

Q2.3 * Please provide details i.e. the population, the extent of decline, where it has taken place, etc.

Q2.4 * What specific interventions resulted in the decline?

Q2.5 * How were these interventions measured?

BEHAVIOURAL SURVEILLANCE

Q2.6 * For which of the following key populations do you have behavioural surveillance data? Please select all that apply:

Behavioural surveillance refers here to the collection of information on risk behaviours relating to HIV, including sexual behaviour.

Men who have sex with men

Migrants (persons born abroad)

People who inject drugs

Prisoners

Sex workers

Trans people

Other key population

No data

[Go to Q2.50](#)

Q2.7 Please specify which other key population:

Men who have sex with men

Your most recent behavioural surveillance

Q2.8 * Is the data:

National

Regional

Cities

Other

Please specify:

Q2.9 * What was the sample size?

Q2.10 * What year was the data collected?

Next round of behavioural surveillance

Q2.11 * Do you have a next round of behavioural surveillance scheduled?

Yes

No

[Go to Q2.14](#)

Q2.12 * Will the data be:

National

Regional

Cities

Other

Please specify:

Q2.13 * What year will the data be collected?

Migrants (persons born abroad)

Your most recent behavioural surveillance

Q2.14 * Is the data:

- National
- Regional
- Cities
- Other

Please specify:

Q2.15 * What was the sample size?

Q2.16 * What year was the data collected?

Next round of behavioural surveillance

Q2.17 * Do you have a next round of behavioural surveillance scheduled?

- Yes
- No [Go to Q2.20](#)

Q2.18 * Will the data be:

- National
- Regional
- Cities
- Other

Please specify:

Q2.19 * What year will the data be collected?

People who inject drugs

Your most recent behavioural surveillance

Q2.20 * Is the data:

- National
- Regional
- Cities
- Other

Please specify:

Q2.21 * What was the sample size?

Q2.22 * What year was the data collected?

Next round of behavioural surveillance

Q2.23 * Do you have a next round of behavioural surveillance scheduled?

- Yes
- No [Go to Q2.26](#)

Q2.24 * Will the data be:

- National
- Regional
- Cities
- Other

Please specify:

Q2.25 * What year will the data be collected?

Prisoners

Your most recent behavioural surveillance

Q2.26 * Is the data:

- National
- Regional
- Cities
- Other

Please specify:

Q2.27 * What was the sample size?

Q2.28 * What year was the data collected?

Next round of behavioural surveillance

Q2.29 * Do you have a next round of behavioural surveillance scheduled?

- Yes
- No

[Go to Q2.32](#)

Q2.30 * Will the data be:

- National
- Regional
- Cities
- Other

Please specify:

Q2.31 * What year will the data be collected?

Sex workers

Your most recent behavioural surveillance

Q2.32 * Is the data:

- National
- Regional
- Cities
- Other

Please specify:

Q2.33 * What was the sample size?

Q2.34 * What year was the data collected?

Next round of behavioural surveillance

Q2.35 * Do you have a next round of behavioural surveillance scheduled?

- Yes
- No

[Go to Q2.38](#)

Q2.36 * Will the data be:

- National
- Regional
- Cities
- Other

Please specify:

Q2.37 * What year will the data be collected?

Trans people

Your most recent behavioural surveillance

Q2.38 * Is the data:

- National
- Regional
- Cities
- Other

Please specify:

Q2.39 * What was the sample size?

Q2.40 * What year was the data collected?

Next round of behavioural surveillance

Q2.41 * Do you have a next round of behavioural surveillance scheduled?

- Yes
- No **Go to Q2.44**

Q2.42 * Will the data be:

- National
- Regional
- Cities
- Other

Please specify:

Q2.43 * What year will the data be collected?

Other key population

Your most recent behavioural surveillance

Q2.44 * Is the data:

- National
- Regional
- Cities
- Other

Please specify:

Q2.45 * What was the sample size?

Q2.46 * What year was the data collected?

Next round of behavioural surveillance

Q2.47 * Do you have a next round of behavioural surveillance scheduled?

- Yes
- No **Go to Q3.1**

Q2.48 * Will the data be:

- National
- Regional
- Cities
- Other

Please specify:

Q2.49 * What year will the data be collected?

SEXUALISED DRUG USE

Q2.50 * What data are available on sexualised drug use (also known as 'chemsex') among men who have sex with men in your country (e.g. overall prevalence, rates of injecting drug use, etc.)? If you do not have data, please state this in the box below. Where you have data, please provide key findings.

Q2.51 * Are specialised drugs services to meet the needs of men who have sex with men engaging in sexualised drug use available in your country?

Yes

No

Go to Q2.53

Q2.52 Please give details:

Go to Q3.1

Q2.53 * Why are they not provided? Please select all that apply:

No evidence of sexualised drug use

Lack of funding

Lack of technical expertise / capacity

Other

Please give details:

Q2.54 * Do you plan to introduce these services within the next 2 years?

Yes

No

PREVENTION

PROVISION OF PREVENTION SERVICES

Please note in this series of questions that 'prisoners' has been replaced with 'prisons'. Consequently, questions should be answered in the context of the location, not the population. For example, estimated coverage should be the percentage of prisons: all prisons, most prisons, some prisons.

Based on the WHO definition of universal health coverage, we define full coverage as 'all who need the service can use it, that the service is of sufficient quality to be effective, and that use of the service will not expose the user to financial hardship'.

Please note this definition when responding to the following questions, and use the following scale:

No coverage: **The service is not provided**

Low coverage: **<30% of the population can use the effective, affordable service**

Medium coverage: **30-60% of the population can use the effective, affordable service**

High coverage: **61-95% of the population can use the effective, affordable service**

Full coverage: **95-100% of the population can use the effective, affordable service**

* What is the estimated coverage of **condom promotion and distribution programmes** for the following key populations?

	No coverage	Low coverage	Medium coverage	High coverage	Full coverage	Don't know
Q3.1a Men who have sex with men	<input type="radio"/>					
Q3.1b Migrants (persons born abroad)	<input type="radio"/>					
Q3.1c Undocumented migrants	<input type="radio"/>					
Q3.1d People who inject drugs	<input type="radio"/>					
Q3.1e Prisons	<input type="radio"/>					
Q3.1f Sex workers	<input type="radio"/>					
Q3.1g Trans people	<input type="radio"/>					
Q3.1h Other key population	<input type="radio"/>					

If relevant, please specify which other key population:

Q3.2 Comments / clarifications:

* What is the estimated coverage of **STI testing and treatment services** for the following key populations?

	No coverage	Low coverage	Medium coverage	High coverage	Full coverage	Don't know
Q3.3a Men who have sex with men	<input type="radio"/>					
Q3.3b Migrants (persons born abroad)	<input type="radio"/>					
Q3.3c Undocumented migrants	<input type="radio"/>					
Q3.3d People who inject drugs	<input type="radio"/>					
Q3.3e Prisons	<input type="radio"/>					
Q3.3f Sex workers	<input type="radio"/>					
Q3.3g Trans people	<input type="radio"/>					
Q3.3h Other key population	<input type="radio"/>					

If relevant, please specify which other key population:

Q3.4 Comments / clarifications:

Q3.12b Hepatitis B

Q3.12c Tetanus

2 As recommended by ECDC guidance

Q3.13 Comments / clarifications:

UPTAKE OF PREVENTION SERVICES

Q3.14 * What data do you have on the following risk behaviours?

Note: Antiretroviral treatment and pre-exposure prophylaxis (PrEP) are having an effect on the risks historically associated with these behaviours. However, at this time, these behaviours remain reasonable measures of potential risk among this population.

Men who have sex with men: Anal sex without condoms with a *non-steady partner* of unknown HIV serostatus

People who inject drugs: Sharing of needles and/or syringes³

People who inject drugs: Anal or vaginal sex without condoms with a *non-steady partner* of unknown HIV serostatus⁴

Sex workers: Anal or vaginal sex without condoms with a *non-steady partner* of unknown HIV serostatus

Trans people: Anal or vaginal sex without condoms with a *non-steady partner* of unknown HIV serostatus

No data [Go to Q3.44](#)

³ Related EMCDDA indicator is "the percent of current IDUs sharing used needles/syringes in the last 4 weeks (receiving or passing on)".

⁴ Related EMCDDA indicator is "the percent of IDUs ever who have reported the use of a condom at last sexual intercourse".

Men who have sex with men: Anal sex without condoms with a *non-steady partner* of unknown HIV serostatus

Q3.15 * Primary data source:

Behavioural surveillance

Project data

Special study

Other

Please give details:

Q3.16 * Were participants asked about use of PrEP:

Yes

No

Don't know

Q3.17 * What were the key findings?

Q3.18 * Is the data:

National

Sub-national

Q3.19 * What is the sample size?

Q3.20 * What year was the data collected?

People who inject drugs: Sharing of needles and/or syringes

Q3.21 * Primary data source:

Behavioural surveillance

Project data

Special study

Other

Please give details:

Q3.22 * What were the key findings?

Q3.23 * Is the data:

National
Sub-national

Q3.24 * What is the sample size?

Q3.25 * What year was the data collected?

People who inject drugs: Anal or vaginal sex without condoms with a *non-steady partner* of unknown HIV serostatus

Q3.26 * Primary data source:

Behavioural surveillance
Project data
Special study
Other

Please give details:

Q3.27 * Were participants asked about use of PrEP?

Yes
No
Don't know

Q3.28 * What were the key findings?

Q3.29 * Is the data:

National
Sub-national

Q3.30 * What is the sample size?

Q3.31 * What year was the data collected?

Sex workers: Anal or vaginal sex without condoms with a *non-steady partner* of unknown HIV serostatus

Q3.32 * Primary data source:

Behavioural surveillance
Project data
Special study
Other

Please give details:

Q3.33 * Were participants asked about use of PrEP?

Yes
No
Don't know

Q3.34 * What were the key findings?

Q3.35 * Is the data:

- National
- Sub-national

Q3.36 * What is the sample size?

Q3.37 * What year was the data collected?

Trans people: Anal or vaginal sex without condoms with a *non-steady partner* of unknown HIV serostatus

Q3.38 * Primary data source:

- Behavioural surveillance
- Project data
- Special study
- Other

Please give details:

Q3.39 * Were participants asked about use of PrEP?

- Yes
- No
- Don't know

Q3.40 * What were the key findings?

Q3.41 * Is the data:

- National
- Sub-national

Q3.42 * What is the sample size?

Q3.43 * What year was the data collected?

SEXUALITY EDUCATION

* Does your country have education policies that guide the delivery of life skills-based HIV and sexuality education⁵, according to international standards⁶, in:

	Yes	No
Q3.44a Primary school	<input type="radio"/>	<input type="radio"/>
Q3.44b Secondary school	<input type="radio"/>	<input type="radio"/>
Q3.44c University	<input type="radio"/>	<input type="radio"/>
Q3.44d Teacher training	<input type="radio"/>	<input type="radio"/>

⁵ An age-appropriate, culturally relevant approach to teaching about sex and relationships by providing scientifically accurate, realistic and non-judgemental information (for more information see UNESCO, UNAIDS, UNFPA, UNICEF, WHO. International technical guidance on sexuality education. Volume I. Paris: UNESCO; 2009.)

⁶ Standardized UNESCO benchmarks for the sexuality education curriculum to ensure quality, including teaching on (1) generic life skills (such as decisionmaking, communication and negotiating skills); (2) sexual and reproductive health and sexuality education (such as human growth and development, relationships, reproductive health, sexual abuse and transmission of sexually transmitted infections); and (3) HIV transmission and prevention.

Q3.45 Comments / clarifications:

PrEP

Q3.46 * Is pre-exposure prophylaxis (PrEP) available in your country?

Yes

No

Go to Q3.48

Q3.47 * How is it available? Please select all that apply:

Included in national policy

Go to Q3.51

Included in clinical guidelines

Provided as part of a pilot project

Prescribed in research

Prescribed in private sector

Available via online purchase

PrEP (cont.)

Q3.48 If there is not yet a national policy for providing PrEP, what stage is your country at in terms of reaching this goal? Please provide details and any barriers to progress.

* What issues are limiting or preventing the implementation of PrEP in your country? What is the level of importance for each issue? Please select all that apply:

	N/A	High	Medium	Low
Q3.49a Adherence	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q3.49b Drug resistance	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q3.49c Feasibility	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q3.49d Cost of the drug	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q3.49e Cost of service delivery	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q3.49f Concerns about lower condom use	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q3.49g Concerns about increased transmission of other sexually transmitted infections	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q3.49h There is no identified group with sufficiently high incidence in accordance with the WHO guidelines	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q3.49i The technical capacity to consider PrEP is limited	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q3.50 If there are other issues limiting or preventing the implementation of PrEP, please provide details:

PrEP (cont.)

Q3.51 * How is PrEP paid for?

- Reimbursed through public sector
- Reimbursed through insurance
- Not reimbursed
- Other

* Please specify:

Q3.52 * Who is PrEP available to?

- MSM at risk of sexual acquisition of HIV
- Heterosexuals at risk of sexual acquisition of HIV
- Sex workers
- Trans people at risk of sexual acquisition of HIV
- Serodiscordant couples (where one partner has a detectable viral load)
- Other

* Please specify:

Q3.53 Comments / clarifications:

Q3.54 * Can people access generic PrEP in your country?

- Yes
- No **Go to Q3.56**

Q3.55 * How do people access generic PrEP in your country?
Please select all that apply:

- Via national health service
- Via local pharmacies
- Online purchase from abroad
- Other

* Please provide details:

Q3.56 * Is there an agreed monitoring system in place to assess uptake and health outcomes of PrEP users?

- Yes
- No **Go to Q3.58**

Q3.57 * Please provide details:

* Are initiatives underway to educate key stakeholders on the use of PrEP as an effective prevention intervention?

	Yes	No	Planned	Don't know
Q3.58a Policy makers	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q3.58b Health ministries / departments	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q3.58c Physicians	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q3.58d Pharmacists	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q3.58e Public health professionals	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q3.58f HIV prevention programmes	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q3.58g Potential PrEP users	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

BARRIERS TO PREVENTION SERVICES

In the previous reporting round, countries were asked whether they had identified barriers to uptake and provision of HIV prevention services.

The barriers listed were:

- Laws or policies
- Lack of data on who should be targeted with prevention messages and services
- Lack of availability of appropriate, population-specific prevention services
- Lack of availability of commodities and supplies
- Lack of sustainable funding for prevention services
- Lack of prevention knowledge and skills among health professionals and programme staff
- Perception of risk among key populations
- Stigma and discrimination among health professionals
- Stigma and discrimination among key populations
- Language and culture

Q3.59 In this round, we would like to know what countries have been doing to address these barriers.

* In the last two years, what has your country done to address barriers to prevention? Please select any of the following that apply, and give details.

Changes to laws or policies (e.g. decriminalisation of sex work or drug use, provision of PrEP, removal of limits on harm reduction services, etc.)

Changes to funding (e.g. increased, made more sustainable, better targeted, etc.)

Improvements in service delivery (e.g. increased supply of commodities such as syringes or condoms, introduction of population-specific services, etc.)

Improvements in monitoring / surveillance

Intervention(s) to improve education / awareness amongst key populations (e.g. publicity campaign, community-based workers and services, etc.)

Intervention(s) to improve education / awareness amongst health professionals (e.g. training on prevention knowledge and skills, etc.)

Intervention(s) to reduce stigma and discrimination

Intervention(s) to reduce barriers presented by differences in language and culture

Other change

No change **Go to Q3.69**

Q3.60 * Please give details of the change to laws or policies and what the results have been. Please specify which key populations are affected by this change:

Q3.61 * Please give details of the change to funding and what the results have been. Please specify which key populations are affected by this change:

Q3.62 * Please give details of the improvements in service delivery and what the results have been. Please specify which key populations are affected by this change:

Q3.63 * Please give details of the improvements in surveillance / monitoring and what the results have been. Please specify which key populations are affected by this change:

Q3.64 * Please give details of the intervention(s) to improve education / awareness amongst key populations and what the results have been. Please specify which key populations are affected by this change*:

Q3.65 * Please give details of the intervention(s) to improve education / awareness amongst health professionals and what the results have been. Please specify which key populations are affected by this change:

Q3.66 * Please give details of the intervention(s) to reduce stigma and discrimination and what the results have been. Please specify which key populations are affected by this change:

Q3.67 * Please give details of the intervention(s) to reduce barriers presented by differences in language and culture and what the results have been. Please specify which key populations are affected by this change:

Q3.68 * Please give details of the other change and what the results have been. Please specify which key populations are affected by this change:

Q3.69 * In the past two years, have any new barriers to uptake or provision of HIV prevention services emerged in your country?

Yes

No

Don't know

Go to Q4.1

Go to Q4.1

Q3.70 * Please give details of the new barriers to uptake or provision of HIV prevention services:

TESTING

NATIONAL TESTING GUIDELINES

- Q4.1 * Are there any national policies or guidelines⁷ in your country that cover HIV testing interventions and strategies? Yes No **Go to Q4.11**

⁷ This could include guidelines on STI testing which have specific mention of HIV testing. Guidelines must be at a national level and be focused on all those at risk of HIV acquisition. Guidelines which discuss testing but do not explicitly mention HIV, or which discuss HIV but do not explicitly mention testing, are not relevant to this question.

- Q4.2 * What year were the guidelines published?

- Q4.3 * Is your country currently considering revisions to the guidelines? Yes No **Go to Q4.5**

- Q4.4 * What year will they be revised?

- Q4.5 * Do the guidelines have content on specific key populations? Yes No **Go to Q4.7**

- Q4.6 * Please provide details:

- Q4.7 * Do the guidelines make recommendations on how often key populations should be tested for HIV? Yes No **Go to Q4.9**

- Q4.8 * Please provide details on testing frequency and population group/s for which it is recommended:

* Are the following HIV testing interventions included in national guidelines?

	Yes	No	Planned
Q4.9a Community-based HIV testing	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q4.9b Self sampling	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q4.9c Self testing	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q4.9d Lay provider HIV testing (i.e. testing administered by someone other than a doctor or nurse)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q4.9e Routine ⁸ antenatal HIV testing	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q4.9f Routine ⁸ HIV testing in sexual health clinics	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q4.9g Provider-initiated HIV testing in primary care (e.g. GPs, family doctors)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q4.9h Provider-initiated HIV testing in secondary care (e.g. emergency departments & other hospital wards)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q4.9i HIV testing in other health settings (e.g. pharmacies)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

⁸ 'Routine' means HIV testing is offered to all patients in this setting

* Are the following HIV testing strategies included in national guidelines?

	Yes	No	Planned
Q4.10a Assisted partner notification ⁹	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q4.10b HIV indicator condition-guided testing



9 The WHO defines 'assisted partner notification' as when consenting HIV-positive clients are assisted by a trained provider to disclose their status or to anonymously notify their sexual and/or drug injecting partner(s) of their potential exposure to HIV infection. The provider then offers HIV testing to these partner(s). Assisted partner notification is done using contact referral, provider referral or dual referral approaches.

Go to Q4.13

Q4.11 * Are there plans to introduce national guidelines which specifically and strategically address HIV testing in the next two years?

Yes

No



Go to Q4.13

Q4.12 * What year will they be introduced?

PROVISION OF TESTING SERVICES (cont.)

Q4.17 * Is HIV testing provided to undocumented migrants in your country?

Yes

No **Go to Q4.19**

Don't know **Go to Q4.19**

Q4.18 * On what basis is testing provided? Please select all that apply:

On the same terms as other people

At an increased cost to the migrant

Provided free of charge

Provision varies

Q4.19 Comments / clarifications:

MONITORING OF TESTING

Q4.20 * Do you collect data to monitor HIV testing interventions in any of the following settings? Please select all that apply:

Community-based HIV testing

Self sampling

Lay provider HIV testing (i.e. testing administered by someone other than a doctor or nurse)

HIV antenatal testing

HIV testing in sexual health clinics

HIV testing in primary care (e.g. GPs, family doctors)

HIV testing in secondary care (e.g. emergency departments & other hospital wards)

HIV testing in other health settings (e.g. pharmacies)

Assisted partner notification

HIV indicator condition-guided testing

No data

[Go to Q4.42](#)

Please provide:

Q4.21 * The absolute number of tests taken via community-based HIV testing in the last 12 months:

Q4.22 * The reactivity rate:

Q4.23 What proportion of new HIV diagnoses in your country are firstly identified, or have a first reactive test performed, in a community-based setting?

Please provide:

Q4.24 * The absolute number of tests taken via self sampling in the last 12 months:

Q4.25 * The reactivity rate:

Please provide:

Q4.26 * The absolute number of tests taken via lay provider testing in the last 12 months:

Q4.27 * The reactivity rate:

Please provide:

Q4.28 * The absolute number of tests taken via antenatal testing in the last 12 months:

Q4.29 * The reactivity rate:

Please provide:

Q4.30 * The absolute number of tests taken via HIV testing in sexual health clinics in the last 12 months:

Q4.31 * The reactivity rate:

Please provide:

Q4.32 * The absolute number of tests taken via HIV testing in primary care in the last 12 months:

Q4.33 * The reactivity rate:

Please provide:

Q4.34 * The absolute number of tests taken via HIV testing in secondary care in the last 12 months:

Q4.35 * The reactivity rate:

Please provide:

Q4.36 * The absolute number of tests taken via HIV testing in other health settings in the last 12 months:

Q4.37 * The reactivity rate:

Please provide:

Q4.38 * The absolute number of tests taken via assisted partner notification in the last 12 months:

Q4.39 * The reactivity rate:

Please provide:

Q4.40 * The absolute number of tests taken via HIV indicator condition-guided testing in the last 12 months:

Q4.41 * The reactivity rate:

BARRIERS TO TESTING SERVICES

In the previous reporting round, countries were asked whether they had identified barriers to uptake and provision of HIV testing services.

The barriers listed were:

- Laws or policies
- Lack of data on who should be recommended for testing
- Lack of availability of HIV testing services
- Lack of availability of community-based testing services
- Lack of availability of home-sampling kits / services
- Lack of availability of self-testing
- Lack of sustainable funding for testing services
- Lack of ability of health professionals to identify and screen asymptomatic patients who should be tested
- Lack of support for or buy-in to HIV testing among key populations
- Stigma and discrimination among health professionals
- Stigma and discrimination among key populations
- Lack of confidentiality
- Language and culture

Q4.42 In this round, we would like to know what countries have been doing to address these barriers.

*** In the last two years, what has your country done to address barriers to testing? Please select any of the following that apply, and give details:**

Changes to laws or policies (e.g. home-sampling, community-based testing, decriminalisation of HIV non-disclosure, etc.)

Changes to funding (e.g. increased, made more sustainable, better targeted, etc.)

Improvements in service delivery (e.g. introduction of point of care testing, routine testing, community-based testing, etc.)

Improvements in monitoring / surveillance

Intervention(s) to improve education / awareness amongst key populations (e.g. publicity campaign, increased buy-in to testing, etc.)

Intervention(s) to improve education / awareness amongst health professionals (e.g. training on screening asymptomatic patients, etc.)

Intervention(s) to reduce stigma and discrimination

Improvements to confidentiality

Intervention(s) to reduce barriers presented by differences in language and culture

Other change

No change

[Go to Q4.53](#)

Q4.43 * Please give details of the changes to laws or policies and what the results have been. Please specify which key populations are affected by this change:

Q4.44 * Please give details of the changes to funding and what the results have been. Please specify which key populations are affected by this change:

Q4.45 * Please give details of the improvements in service delivery and what the results have been. Please specify which key populations are affected by this change:

Q4.46 * Please give details of the Improvements in monitoring / surveillance and what the results have been. Please specify which key populations are affected by this change:

Q4.47 * Please give details of the intervention(s) to improve education / awareness amongst key populations and what the results have been. Please specify which key populations are affected by this change:

Q4.48 * Please give details of the intervention(s) to improve education / awareness amongst health professionals and what the results have been. Please specify which key populations are affected by this change:

Q4.49 * Please give details of the intervention(s) to reduce stigma and discrimination and what the results have been. Please specify which key populations are affected by this change:

Q4.50 * Please give details of the improvements to confidentiality and what the results have been. Please specify which key populations are affected by this change:

Q4.51 * Please give details of the intervention(s) to reduce barriers presented by differences in language and culture and what the results have been. Please specify which key populations are affected by this change:

Q4.52 * Please give details of the other change and what the results have been. Please specify which key populations are affected by this change:

Q4.53 * In the past two years, have any new barriers to uptake or provision of HIV testing services emerged in your country?:

Yes

No

Don't know

[Go to Q5.1](#)

[Go to Q5.1](#)

Q4.54 * Please give details of the new barriers to uptake or provision of HIV testing services:

TREATMENT

NATIONAL TREATMENT GUIDANCE

- Q5.1 * Are there any national policies or guidelines¹⁹ in your country that cover HIV treatment? Yes No **Go to Q5.5**
- ¹⁰ This could include guidelines on STI treatment which have specific mention of HIV treatment. Guidelines must be at a national level and be focused on all adults living with HIV. Guidelines which discuss treatment but do not explicitly mention HIV, or which discuss HIV but do not explicitly mention treatment, are not relevant to this question.**
- Q5.2 * What year were they published?
- Q5.3 * Is your country currently considering revisions to the guidelines? Yes No **Go to Q5.7**
- Q5.4 * What year will they be revised? **Go to Q5.7**
- Q5.5 * Are there plans to introduce national guidelines which specifically and strategically address HIV treatment in the next two years? Yes No **Go to Q5.7**
- Q5.6 * What year will they be introduced?
- Q5.7 * Does your country have a national policy on the frequency of clinic visits for people who are stable on antiretroviral therapy? Yes No **Go to Q5.9**
- Q5.8 * Please specify the frequency of clinic visits included in the national policy:
- Once a month
- Every 3 months
- Every 6 months
- Every 12 months
- Other
- Please provide details:
- Q5.9 * Do national policies exclude undocumented migrants from receiving HIV treatment in your country? Yes No

PROVISION OF TREATMENT

Q5.10 * Is HIV treatment provided to undocumented migrants in your country?

Yes

Provision varies

No

Go to Q5.12

Q5.11 * How is treatment provided? Please select all that apply:

Provided on the same terms as other people

Provided at an increased cost to the migrant

Provided free of charge

Q5.12 Comments / clarifications:

Q5.13 * Is HIV treatment provided to prisoners in your country?

Yes

Provision varies

No

Q5.14 Comments / clarifications:

Q5.15 * Is HIV treatment provided to people who inject drugs in your country?

Yes

Provision varies

No

Q5.16 Comments / clarifications:

BARRIERS TO TREATMENT

In the previous reporting round, countries were asked whether they had identified barriers to uptake and provision of HIV treatment services.

The barriers listed were:

- Laws or policies
- Lack of systems / referral mechanisms to link people diagnosed with HIV to treatment programmes
- Lack of availability of treatment programmes
- Lack of availability of drugs and tailored drug regimens
- Lack of integration with other health services and support services
- Lack of treatment-related knowledge and skills among health professionals
- Perception of risk among key populations
- Issues with adherence and retention
- Stigma and discrimination among health professionals
- Stigma and discrimination among key populations
- Lack of confidentiality
- Language and culture

Q5.17 In this round, we would like to know what countries have been doing to address these barriers.

* In the last two years, what has your country done to address barriers to treatment? Please select any of the following that apply, and give details:

Changes to laws or policies (e.g. provision of ART to undocumented migrants, immediate initiation of ART, etc.)

Changes to funding (e.g. increased, made more sustainable, better targeted, etc.)

Reductions in treatment costs (e.g. provision of generics, etc.)

Improvements in service delivery (e.g. increased availability of treatment programmes / drugs, improved referral mechanisms / linkage to care, etc.)

Increased integration with other health services (e.g. treatment for non-communicable diseases (NCDs)) or support services (e.g. substance abuse, nutrition, housing)

Intervention(s) to improve education / awareness amongst key populations

Intervention(s) to improve education / awareness amongst health professionals (e.g. training on treatment-related knowledge and skills)

Intervention(s) to improve adherence

Intervention(s) to improve retention

Intervention(s) to reduce stigma and discrimination

Improvements to confidentiality

Intervention(s) to reduce barriers presented by differences in language and culture

Other change

No change

[Go to Q5.31](#)

Q5.18 * Please give details of the changes to laws or policies and what the results have been. Please specify which key populations are affected by this change:

Q5.19 * Please give details of the changes to funding and what the results have been. Please specify which key populations are affected by this change:

Q5.20 * Please give details of the reduction in treatment costs and what the results have been. Please specify which key populations are affected by this change:

Q5.21 * Please give details of the improvements in service delivery and what the results have been. Please specify which key populations are affected by this change:

Q5.22 * Please give details of the increased integration with other health services or support services and what the results have been. Please specify which key populations are affected by this change:

Q5.23 * Please give details of the intervention(s) to improve education / awareness amongst key populations and what the results have been. Please specify which key populations are affected by this change:

Q5.24 * Please give details of the intervention(s) to improve education / awareness amongst health professionals and what the results have been. Please specify which key populations are affected by this change:

Q5.25 * Please give details of the intervention(s) to improve adherence and what the results have been. Please specify which key populations are affected by this change:

Q5.26 * Please give details of the intervention(s) to improve retention and what the results have been. Please specify which key populations are affected by this change:

Q5.27 * Please give details of the intervention(s) to reduce stigma and discrimination and what the results have been. Please specify which key populations are affected by this change:

Q5.28 * Please give details of the improvements to confidentiality and what the results have been. Please specify which key populations are affected by this change:

Q5.29 * Please give details of the intervention(s) to reduce barriers presented by differences in language and culture and what the results have been. Please specify which key populations are affected by this change:

Q5.30 * Please give details of the other change and what the results have been. Please specify which key populations are affected by this change:

Q5.31 * In the past two years, have any new barriers to uptake or provision of HIV treatment services emerged in your country?:

Yes

No

Don't know

[Go to Q6.1](#)

[Go to Q6.1](#)

Q5.32 * Please give details of the new barriers to uptake or provision of HIV testing services:

CONTINUUM OF CARE

Definitions for each of the four stages in the continuum

Stage 1: Total estimated number of people living with HIV in the country

The total estimated number should be based on an empirical modelling approach, using the ECDC HIV Modelling Tool, Spectrum or any other empirical estimate. The estimate should include diagnosed and undiagnosed people.

Stage 2: Number/percentage of above (estimated number of people living with HIV in the country) who are living with diagnosed HIV

The number should include all new HIV or AIDS diagnoses. It should also include those people who are in care and those who have not been linked to care.

Stage 3: Number/percentage of above (estimated number of people living with HIV in the country, who have been diagnosed) who are currently on antiretroviral treatment

Number with at least one record of ART (prescribed or, ideally, dispensed) by year end, regardless of treatment eligibility criteria. ART is defined as any ART regimen since diagnosis, regardless of the number of antiretroviral drugs.

Stage 4: Number/percentage of above (estimated number of people living with HIV in the country, who have been diagnosed, who are currently on antiretroviral treatment) who had VL \leq 200 copies/ml at last visit (virally suppressed)

Number on ART whose most recent HIV RNA measurement at year end was <200 copies/ml, or below the level of detection of the assay.

Where possible, deaths and out-migration should be excluded from reported data.

Further detail on the definition of the continuum care can be found in this paper from ECDC.

CONTINUUM OF CARE DATA

- Q6.1 * For which of the following key populations do you have data for any stage of continuum of care data? Please select all that apply:
- All people living with HIV
 - Men who have sex with men
 - Migrants (persons born abroad)
 - People who inject drugs
 - Prisoners
 - Sex workers
 - Trans people
 - No data [Go to Q6.201](#)

All people living with HIV

Q6.2 * For which of the stages can you provide continuum of care data for all people living with HIV?

Stage 1: What is the total estimated number of people living with HIV in your country?

Stage 2: What is the number of people living with HIV who have been diagnosed?

Stage 3: What is the number of people living with HIV who are currently on ART?

Stage 4: What is the number of people living with HIV who had VL \leq 200 copies/ml at their last visit?

Q6.3 * **Stage 1: What is the total estimated number of people living with HIV in your country?**

Q6.4 Please provide uncertainty bounds for this figure:

Q6.5 * What year does this estimated figure relate to?

Q6.6 * Primary data source:

ECDC modelling tool

SPECTRUM modelling tool

Other modelling tool

Other estimate

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.7a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.7b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.8 * How confident are you that the figure provided for stage 1 is accurate and representative of all people living with HIV?

High

Medium

Low

Q6.9 * **Stage 2: What is the number of people living with HIV who have been diagnosed?**

Q6.10 What percentage is this of the number of people living with HIV? (%)

Q6.11 * What year was this data collected?

Q6.12 * Primary data source:

Cohort data

Surveillance data

Other data source

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.13a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.13b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.14 * How confident are you that the figure provided for stage 2 is accurate and representative of all people living with HIV?

High

Medium

Low

Q6.15 * **Stage 3: What is the number of people living with HIV who are currently on ART?**

Q6.16 What percentage is this of the number of people living with HIV who have been diagnosed? (%)

Q6.17 * What year was this data collected?

Q6.18 * Primary data source:

Cohort data

Surveillance data

Other data source

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.19a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.19b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.20 * How confident are you that the figure provided for stage 3 is accurate and representative of all people living with HIV?

High

Medium

Low

Q6.21 * **Stage 4: What is the number of people living with HIV who had VL ≤200 copies/ml at their last visit?**

Q6.22 What percentage is this of the number of people who are currently on ART? (%)

Q6.23 * What year was this data collected?

Q6.24 * Primary data source:

Cohort data

Surveillance data

Other data source

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.25a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.25b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.26 * How confident are you that the figure provided for stage 4 is accurate and representative of all people living with HIV?

High

Medium

Low

If you have been unable to provide data for any stage of the continuum for this key population, please identify the reasons why your country does not have data to report. Please select all that apply:

	Stage 1	Stage 2	Stage 3	Stage 4
Q6.27a No data is available	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.27b Not clear what data to report	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.27c Data is not used to monitor the HIV response	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.27d Accuracy of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Q6.27e	Representativeness of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.27f	Timeliness of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.27g	Insufficient resources to collect the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.27h	Insufficient resources to analyse the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.27i	Insufficient resources to report the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Q6.28 If there are other reasons to those outlined above, please provide them here:

Q6.29 Comments / clarifications:

Men who have sex with men

Q6.30 * For which of the stages can you provide continuum of care data for all men who have sex with men?

Stage 1: What is the total estimated number of men who have sex with men living with HIV in your country?

Stage 2: What is the number of men who have sex with men living with diagnosed HIV?

Stage 3: What is the number of men who have sex with men who are currently on ART?

Stage 4: What is the number of men who have sex with men who had VL \leq 200 copies/ml at their last visit?

Q6.31 * **Stage 1: What is the total estimated number of men who have sex with men living with HIV in your country?**

Q6.32 Please provide uncertainty bounds for this figure:

Q6.33 * What year does this estimated figure relate to?

Q6.34 * Primary data source:

ECDC modelling tool

SPECTRUM modelling tool

Other modelling tool

Other estimate

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.35a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.35b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
----------------------	-----------------------	-----------------------	-----------------------	-----------------------

Q6.36 * How confident are you that the figure provided for Stage 1 is accurate and representative of all men who have sex with men living with HIV?

High

Medium

Low

Q6.37 * **Stage 2: What is the number of men who have sex with men living with diagnosed HIV?**

Q6.38 What percentage is this of the number of men who have sex with men living with HIV? (%)

Q6.39 * What year was this data collected?

Q6.40 * Primary data source:

Cohort data

Surveillance data

Other data source

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.41a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.41b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
----------------------	-----------------------	-----------------------	-----------------------	-----------------------

Q6.42 * How confident are you that the figure provided for Stage 2 is accurate and representative of all men who have sex with men living with HIV?

High

Medium

Low

Q6.43 * **Stage 3: What is the number of men who have sex with men who are currently on ART?**

Q6.44 What percentage is this of the number of men who have sex with men living with diagnosed HIV? (%)

Q6.45 * What year was this data collected?

Q6.46 * Primary data source:

Cohort data

Surveillance data

Other data source

Q6.47 Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.48a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.48b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.49 * How confident are you that the figure provided for Stage 3 is accurate and representative of all men who have sex with men living with HIV?

High

Medium

Low

Q6.50 * **Stage 4: What is the number of men who have sex with men who had VL \leq 200 copies/ml at their last visit?**

Q6.51 What percentage is this of the number of men who have sex with men who are currently on ART? (%)

Q6.52 * What year was this data collected?

Q6.53 * Primary data source:

Cohort data

Surveillance data

Other data source

Q6.54 Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.55a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.55b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.56 * How confident are you that the figure provided for Stage 4 is accurate and representative of all men who have sex with men living with HIV?

High

Medium

Low

If you have been unable to provide data for any stage of the continuum for this key population, please identify the reasons why your country does not have data to report. Please select all that apply:

	Stage 1	Stage 2	Stage 3	Stage 4
Q6.57a No data is available	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.57b Not clear what data to report	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.57c Data is not used to monitor the HIV response	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Q6.57d	Accuracy of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.57e	Representativeness of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.57f	Timeliness of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.57g	Insufficient resources to collect the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.57h	Insufficient resources to analyse the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.57i	Insufficient resources to report the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Q6.58 If there are other reasons to those outlined above, please provide them here:

Q6.59 Comments / clarifications:

Migrants (persons born abroad)

Q6.60 * For which of the stages can you provide continuum of care data for migrants (persons born abroad) living with HIV?

Stage 1: What is the total estimated number of migrants (persons born abroad) living with HIV in your country?

Stage 2: What is the number of migrants (persons born abroad) living with diagnosed HIV?

Stage 3: What is the number of migrants (persons born abroad) who are currently on ART?

Stage 4: What is the number of migrants (persons born abroad) who had VL \leq 200 copies/ml at their last visit?

Q6.61 * **Stage 1: What is the total estimated number of migrants (persons born abroad) living with HIV in your country?**

Q6.62 Please provide uncertainty bounds for this figure:

Q6.63 * Which year does this estimated figure relate to?

Q6.64 * Primary data source:

ECDC modelling tool

SPECTRUM modelling tool

Other modelling tool

Other estimate

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.65a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.65b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.66 * How confident are you that the figure provided for Stage 1 is accurate and representative of all migrants (persons born abroad) living with HIV?

High

Medium

Low

Q6.67 * **Stage 2: What is the number of migrants (persons born abroad) living with diagnosed HIV?**

Q6.68 What percentage is this of the number of migrants (persons born abroad) living with HIV? (%)

Q6.69 * What year was this data collected?

Q6.70 * Primary data source:

Cohort data

Surveillance data

Other data source

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.71a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.71b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.72 * How confident are you that the figure provided for Stage 2 is accurate and representative of all migrants (persons born abroad) living with HIV? High
 Medium
 Low

Q6.73 * **Stage 3: What is the number of migrants (persons born abroad) who are currently on ART?**

Q6.74 What percentage is this of the number of migrants (persons born abroad) living with diagnosed HIV? (%)

Q6.75 * What year was this data collected?

Q6.76 * Primary data source: Cohort data
 Surveillance data
 Other data source

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.77a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.77b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.78 * How confident are you that the figure provided for Stage 3 is accurate and representative of all migrants (persons born abroad) living with HIV? High
 Medium
 Low

Q6.79 * **Stage 4: What is the number of migrants (persons born abroad) who had VL ≤200 copies/ml at their last visit?**

Q6.80 What percentage is this of the number of migrants (persons born abroad) who are currently on ART? (%)

Q6.81 * What year was this data collected?

Q6.82 * Primary data source: Cohort data
 Surveillance data
 Other data source

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.83a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.83b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.84 * How confident are you that the figure provided for Stage 4 is accurate and representative of all migrants (persons born abroad) living with HIV? High
 Medium
 Low

If you have been unable to provide data for any stage of the continuum for this key population, please identify the reasons why your country does not have data to report. Please select all that apply:

	Stage 1	Stage 2	Stage 3	Stage 4
Q6.85a No data is available	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Q6.85b	Not clear what data to report	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.85c	Data is not used to monitor the HIV response	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.85d	Accuracy of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.85e	Representativeness of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.85f	Timeliness of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.85g	Insufficient resources to collect the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.85h	Insufficient resources to analyse the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.85i	Insufficient resources to report the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Q6.86 If there are other reasons to those outlined above, please provide them here:

Q6.87 Comments / clarifications:

People who inject drugs

Q6.88 * For which of the stages can you provide continuum of care data for people who inject drugs living with HIV?

Stage 1: What is the total estimated number of people who inject drugs living with HIV in your country?

Stage 2: What is the number of people who inject drugs living with diagnosed HIV?

Stage 3: What is the number of people who inject drugs who are currently on ART?

Stage 4: What is the number of people who inject drugs who had VL \leq 200 copies/ml at their last visit?

Q6.89 * **Stage 1: What is the total estimated number of people who inject drugs living with HIV in your country?**

Q6.90 Please provide uncertainty bounds for this figure:

Q6.91 * Which year does this estimated figure relate to?

Q6.92 * Primary data source:

ECDC modelling tool

SPECTRUM modelling tool

Other modelling tool

Other estimate

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.93a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.93b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
----------------------	-----------------------	-----------------------	-----------------------	-----------------------

Q6.94 * How confident are you that the figure provided for stage 1 is accurate and representative of all people who inject drugs living with HIV?

High

Medium

Low

Q6.95 * **Stage 2: What is the number of people who inject drugs living with diagnosed HIV?**

Q6.96 What percentage is this of the number of people who inject drugs living with HIV? (%)

Q6.97 * What year was this data collected?

Q6.98 * Primary data source:

Cohort data

Surveillance data

Other data source

Q6.99 Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.100a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.100b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
-----------------------	-----------------------	-----------------------	-----------------------	-----------------------

Q6.101 * How confident are you that the figure provided for stage 2 is accurate and representative of all people who inject drugs living with HIV? High
 Medium
 Low

Q6.102 * **Stage 3: What is the number of people who inject drugs who are currently on ART?**

Q6.103 What percentage is this of the number of people who inject drugs living with diagnosed HIV? (%)

Q6.104 * What year was this data collected?

Q6.105 * Primary data source: Cohort data
 Surveillance data
 Other data source

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.106a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.106b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.107 * How confident are you that the figure provided for stage 3 is accurate and representative of all people who inject drugs living with HIV? High
 Medium
 Low

Q6.108 * **Stage 4: What is the number of the above who had VL ≤200 copies/ml at their last visit?**

Q6.109 What percentage is this of the number of people who inject drugs who are currently on ART? (%)

Q6.110 * What year was this data collected?

Q6.111 * Primary data source: Cohort data
 Surveillance data
 Other data source

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.112a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.112b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.113 * How confident are you that the figure provided for stage 4 is accurate and representative of all people who inject drugs living with HIV? High
 Medium
 Low

If you have been unable to provide data for any stage of the continuum for this key population, please identify the reasons why your country does not have data to report. Please select all that apply:

	Stage 1	Stage 2	Stage 3	Stage 4
Q6.114a No data is available	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Q6.114b Not clear what data to report	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.114c Data is not used to monitor the HIV response	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.114d Accuracy of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.114e Representativeness of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.114f Timeliness of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.114g Insufficient resources to collect the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.114h Insufficient resources to analyse the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.114i Insufficient resources to report the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Q6.115 If there are other reasons to those outlined above, please provide them here:

Q6.116 Comments / clarifications:

Prisoners

Q6.117 * For which of the stages can you provide continuum of care data for prisoners living with HIV?

Stage 1: What is the total estimated number of prisoners living with HIV in your country?

Stage 2: What is the number of prisoners living with diagnosed HIV?

Stage 3: What is the number of prisoners who are currently on ART?

Stage 4: What is the number of prisoners who had VL \leq 200 copies/ml at their last visit?

Q6.118 * **Stage 1: What is the total estimated number of prisoners living with HIV in your country?**

Q6.119 Please provide uncertainty bounds for this figure:

Q6.120 * Which year does this estimated figure relate to?

Q6.121 * Primary data source:

ECDC modelling tool

SPECTRUM modelling tool

Other modelling tool

Other estimate

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.122a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.122b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.123 * How confident are you that the figure provided for stage 1 is accurate and representative of all prisoners living with HIV?

High

Medium

Low

Q6.124 * **Stage 2: What is the number of prisoners living with diagnosed HIV?**

Q6.125 What percentage is this of the number of prisoners living with HIV? (%)

Q6.126 * What year was this data collected?

Q6.127 * Primary data source:

Cohort data

Surveillance data

Other data source

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.128a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.128b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.129 * How confident are you that the figure provided for stage 2 is accurate and representative of all prisoners living with HIV?

High

Medium

Low

Q6.130 * **Stage 3: What is the number of prisoners who are currently on ART?**

Q6.131 What percentage is this of the number of prisoners living with diagnosed HIV? (%)

Q6.132 * What year was this data collected?

Q6.133 * Primary data source: Cohort data
Surveillance data
Other data source

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.134a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.134b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.135 * How confident are you that the figure provided for stage 3 is accurate and representative of all prisoners living with HIV? High
Medium
Low

Q6.136 * **Stage 4: What is the number of prisoners who had VL \leq 200 copies/ml at their last visit?**

Q6.137 What percentage is this of the number of prisoners who are currently on ART? (%)

Q6.138 * What year was this data collected?

Q6.139 * Primary data source: Cohort data
Surveillance data
Other data source

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.140a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.140b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.141 * How confident are you that the figure provided for stage 4 is accurate and representative of all prisoners living with HIV? High
Medium
Low

If you have been unable to provide data for any stage of the continuum for this key population, please identify the reasons why your country does not have data to report. Please select all that apply:

	Stage 1	Stage 2	Stage 3	Stage 4
Q6.142a No data is available	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.142b Not clear what data to report	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.142c Data is not used to monitor the HIV response	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.142d Accuracy of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Q6.142e Representativeness of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.142f Timeliness of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.142g Insufficient resources to collect the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.142h Insufficient resources to analyse the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.142i Insufficient resources to report the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Q6.143 If there are other reasons to those outlined above, please provide them here:

Q6.144 Comments / clarifications:

Sex workers

Q6.145 * For which of the stages can you provide continuum of care data for sex workers living with HIV?

Stage 1: What is the total estimated number of sex workers living with HIV in your country?

Stage 2: What is the number of sex workers living with diagnosed HIV?

Stage 3: What is the number of sex workers who are currently on ART?

Stage 4: What is the number of sex workers who had VL ≤200 copies/ml at their last visit?

Q6.146 * **Stage 1: What is the total estimated number of sex workers living with HIV in your country?**

Q6.147 Please provide uncertainty bounds for this figure:

Q6.148 * Which year does this estimated figure relate to?

Q6.149 * Primary data source:

ECDC modelling tool

SPECTRUM modelling tool

Other modelling tool

Other estimate

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.150a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.150b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.151 * How confident are you that the figure provided for stage 1 is accurate and representative of all sex workers living with HIV?

High

Medium

Low

Q6.152 * **Stage 2: What is the number of sex workers living with diagnosed HIV?**

Q6.153 What percentage is this of the number of sex workers living with HIV? (%)

Q6.154 * What year was this data collected?

Q6.155 * Primary data source:

Cohort data

Surveillance data

Other data source

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.156a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.156b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.157 * How confident are you that the figure provided for stage 2 is accurate and representative of all sex workers living with HIV?

High

Medium

Low

Q6.158 * **Stage 3: What is the number of sex workers who are currently on ART?**

Q6.159 What percentage is this of the number of sex workers living with diagnosed HIV? (%)

Q6.160 * What year was this data collected?

Q6.161 * Primary data source:

Cohort data

Surveillance data

Other data source

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.162a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.162b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.163 * How confident are you that the figure provided for stage 3 is accurate and representative of all sex workers living with HIV?

High

Medium

Low

Q6.164 * **Stage 4: What is the number of sex workers who had VL ≤200 copies/ml at their last visit?**

Q6.165 What percentage is this of the number of sex workers who are currently on ART? (%)

Q6.166 * What year was this data collected?

Q6.167 * Primary data source:

Cohort data

Surveillance data

Other data source

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.168a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.168b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.169 * How confident are you that the figure provided for stage 4 is accurate and representative of all sex workers living with HIV?

High

Medium

Low

If you have been unable to provide data for any stage of the continuum for this key population, please identify the reasons why your country does not have data to report. Please select all that apply:

	Stage 1	Stage 2	Stage 3	Stage 4
Q6.170a No data is available	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.170b Not clear what data to report	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.170c Data is not used to monitor the HIV response	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.170d Accuracy of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Q6.170e Representativeness of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.170f Timeliness of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.170g Insufficient resources to collect the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.170h Insufficient resources to analyse the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.170i Insufficient resources to report the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Q6.171 If there are other reasons to those outlined above, please provide them here:

Q6.172 Comments / clarifications:

Trans people

Q6.173 * For which of the stages can you provide continuum of care data for trans people living with HIV?

Stage 1: What is the total estimated number of trans people living with HIV in your country?

Stage 2: What is the number of trans people living with diagnosed HIV?

Stage 3: What is the number of trans people who are currently on ART?

Stage 4: What is the number of trans people who had VL \leq 200 copies/ml at their last visit?

Q6.174 * **Stage 1: What is the total estimated number of trans people living with HIV in your country?**

Q6.175 Please provide uncertainty bounds for this figure:

Q6.176 * Which year does this estimated figure relate to?

Q6.177 * Primary data source:

ECDC modelling tool

SPECTRUM modelling tool

Other modelling tool

Other estimate

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.178a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.178b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
-----------------------	-----------------------	-----------------------	-----------------------	-----------------------

Q6.179 * How confident are you that the figure provided for stage 1 is accurate and representative of all trans people living with HIV?

High

Medium

Low

Q6.180 * **Stage 2: What is the number of trans people living with diagnosed HIV?**

Q6.181 What percentage is this of the number of trans people living with HIV? (%)

Q6.182 * What year was this data collected?

Q6.183 * Primary data source:

Cohort data

Surveillance data

Other data source

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.184a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.184b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
-----------------------	-----------------------	-----------------------	-----------------------	-----------------------

Q6.185 * How confident are you that the figure provided for stage 2 is accurate and representative of all trans people living with HIV?

High

Medium

Low

Q6.186 * **Stage 3: What is the number of trans people who are currently on ART?**

Q6.187 What percentage is this of the number of trans people living with diagnosed HIV? (%)

Q6.188 * What year was this data collected?

Q6.189 * Primary data source: Cohort data
Surveillance data
Other data source

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.190a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.190b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.191 * How confident are you that the figure provided for stage 3 is accurate and representative of all trans people living with HIV? High
Medium
Low

Q6.192 * **Stage 4: What is the number of trans people who had VL \leq 200 copies/ml at their last visit?**

Q6.193 What percentage is this of the number of trans people who are currently on ART? (%)

Q6.194 * What year was this data collected?

Q6.195 * Primary data source: Cohort data
Surveillance data
Other data source

Please give details:

* Were you able to exclude the following?

	Yes	No	Partially	Don't know
Q6.196a Deaths	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.196b Out-migration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6.197 * How confident are you that the figure provided for stage 4 is accurate and representative of all trans people living with HIV? High
Medium
Low

If you have been unable to provide data for any stage of the continuum for this key population, please identify the reasons why your country does not have data to report. Please select all that apply:

	Stage 1	Stage 2	Stage 3	Stage 4
Q6.198a No data is available	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.198b Not clear what data to report	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.198c Data is not used to monitor the HIV response	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.198d Accuracy of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Q6.198e Representativeness of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.198f Timeliness of the available data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.198g Insufficient resources to collect the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.198h Insufficient resources to analyse the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6.198i Insufficient resources to report the data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Q6.199 If there are other reasons to those outlined above, please provide them here:

Q6.200 Comments / clarifications:

Q6.201 * Would you like technical support from ECDC to help you provide data for the continuum of care in the next reporting round?

Yes

No



If you select 'Yes', an ECDC representative will contact you to discuss the kind of support you need.

LINKAGE TO CARE

ECDC uses the following definition for linkage to care: patient entry into specialist HIV care after diagnosis, measured as the time between the HIV diagnosis date and either the first clinic attendance date, first CD4 count or viral load date, or HIV treatment start date, depending on data availability; linkage is considered prompt if within 3 months of diagnosis.

Q6.202 * What data do you have on linkage to care?

Of all those diagnosed with HIV in your country in the last 12 months, what proportion have been linked to care? (%)

Of all those diagnosed with HIV in your country in the last 12 months, what proportion have been promptly linked to care? (%)

No data

[Go to Q6.206](#)

Q6.203 Of all those diagnosed with HIV in your country in the last 12 months, what proportion have been linked to care? (%)

Q6.204 Of all those diagnosed with HIV in your country in the last 12 months, what proportion have been promptly linked to care? (%)

Q6.205 * What type of data did you use when calculating the proportion of those linked to care? Please select all that apply:

Time between HIV diagnosis date and first clinic attendance date

Time between HIV diagnosis date and first CD4 count or viral load date

Time between HIV diagnosis date and HIV treatment start date

Q6.206 * What is the average¹¹ length of time between a reactive HIV test and date of first contact with whoever is responsible for initial care (e.g. date of first CD4 test, viral load test or start of ART)?

No data

[Go to Q6.207](#)

Within one week of reactive test

Within two weeks of reactive test

Within one month of reactive test

Within three months of reactive test

Within six months of reactive test

Other

¹¹ Please use the 'mode' average

Please give details:

Q6.207 * What is the average¹² length of time between a confirmed HIV diagnosis and the start of treatment?

No data

[Go to Q6.208](#)

Within one week of diagnosis

Within two weeks of diagnosis

Within one month of diagnosis

Within three months of diagnosis

Other

¹² Please use the 'mode' average

Please give details:

ADHERENCE

- Q6.208 * Do you have a definition for 'adherence' in your country? Yes
 No

[Go to Q6.211](#)

- Q6.209 * What is the definition for 'adherence' used in your country?

- Q6.210 * How are adherence rates calculated in your country?

- Q6.211 * What measures are used to track adherence? Please select all that apply:

- Adherence not tracked
Viral suppression
Patient self reporting
Prescription data
Other measure

Please give details:

ADHERENCE (cont.)

Q6.212 * For which of the following key populations do you have data on adherence rates? (please select all that apply):

All people living with HIV

Men who have sex with men

Migrants (persons born abroad)

Undocumented migrants

People who inject drugs

Prisoners

Sex workers

Trans people

Other key population

No data

[Go to Q6.233](#)

Please specify which other key population:

All people living with HIV

Q6.213 * What is the adherence rate? (%)

Q6.214 * What year was this data collected?

Men who have sex with men

Q6.215 * What is the adherence rate? (%)

Q6.216 * What year was this data collected?

Migrants (persons born abroad)

Q6.217 * What is the adherence rate? (%)

Q6.218 * What year was this data collected?

Undocumented migrants

Q6.219 * What is the adherence rate? (%)

Q6.220 * What year was this data collected?

People who inject drugs

Q6.221 * What is the adherence rate? (%)

Q6.222 * What year was this data collected?

Prisoners

Q6.223 * What is the adherence rate? (%)

Q6.224 * What year was this data collected?

Sex workers

Q6.225 * What is the adherence rate? (%)

Q6.226 * What year was this data collected?

Trans people

Q6.227 * What is the adherence rate? (%)

Q6.228 * What year was this data collected?

Other key population

Q6.229 * What is the adherence rate? (%)

Q6.230 * What year was this data collected?

RETENTION

Q6.231 * Do you have a definition for 'retention in care' in your country?

Yes

No

[Go to Q6.234](#)

Q6.232 * What is the definition for 'retention in care' used in your country?

Q6.233 * How are retention rates calculated in your country?

Q6.234 * What measures are used to track retention? Please select all that apply:

Retention not tracked

Viral load measurements

Viral suppression

Prescription data

Insurance data

Doctor visits

Gaps in care

Other measure

Please give details:

RETENTION (cont.)

Q6.235 * For which of the following key populations do you have data on retention rates?

All people living with HIV

Men who have sex with men

Migrants (persons born abroad)

Undocumented migrants

People who inject drugs

Prisoners

Sex workers

Trans people

Other key population

No data

[Go to Q6.254](#)

Please specify which other key population:

All people living with HIV

Q6.236 * What is the retention rate? (%)

Q6.237 * What year was this data collected?

Men who have sex with men

Q6.238 * What is the retention rate? (%)

Q6.239 * What year was this data collected?

Migrants (persons born abroad)

Q6.240 * What is the retention rate? (%)

Q6.241 * What year was this data collected?

Undocumented migrants

Q6.242 * What is the retention rate? (%)

Q6.243 * What year was this data collected?

People who inject drugs

Q6.244 * What is the retention rate? (%)

Q6.245 * What year was this data collected?

Prisoners

Q6.246 * What is the retention rate? (%)

Q6.247 * What year was this data collected?

Sex workers

Q6.248 * What is the retention rate? (%)

Q6.249 * What year was this data collected?

Trans people

Q6.250 * What is the retention rate? (%)

Q6.251 * What year was this data collected?

Other key population

Q6.252 * What is the retention rate? (%)

Q6.253 * What year was this data collected?

QUALITY OF CARE

* Are systems in place to ensure that people living with HIV who are on treatment are linked to other care programmes and services?

	Fully in place	Partially in place	Not in place	Don't know
Q6.254a HIV support services - how to disclose, living with HIV, how to take medication correctly/on time, relationship/sex advice, etc.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.254b Substance abuse (drugs and alcohol)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.254c Mental health	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.254d Sexual and reproductive health	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.254e Hepatitis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.254f Tuberculosis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.254g Vaccinations	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.254h Long-term condition management	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.254i Nutrition and weight management	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.254j Health literacy ¹³	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.254k Peer support	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.254l Smoking cessation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.254m Housing support	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.254n Employment and careers advice / support	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.254o Financial and social security advice	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.254p Legal advice	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.254q Immigration support	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.254r Support for those leaving prison	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q6.254s Domestic violence support	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

¹³ Health literacy can be defined as the capacity that an individual has to access and effectively use health-related information, in order to promote and maintain good health.

Q6.255	* Does national HIV monitoring include measurement of health-related quality of life of people living with HIV?	Yes	<input type="radio"/>
		No	<input type="radio"/> Go to Q7.1
Q6.256	* Which indicator(s), tool or index is used to measure quality of life?	<input type="text"/>	
Q6.257	* Does monitoring compare the quality of life of PLHIV to the quality of life of the general population?	Yes	<input type="radio"/>
		No	<input type="radio"/>
Q6.258	* What year was quality-of-life monitoring data last collected?	<input type="text"/>	

SPENDING

Please note, in this section 'expenditure' refers to all spending, including management, programme implementation, service delivery, drugs and commodities

Q7.1 * Do you have data on the following:

- Total expenditure
- Expenditure on national programmes
- Expenditure on sub-national programmes
- No data [Go to Q7.12a](#)

Total expenditure

Q7.2 * Amount

Q7.3 * Currency

Q7.4 * Year

National expenditure

Q7.5 * Amount

Q7.6 * Currency

Q7.7 * Year

Sub-national expenditure

Q7.8 * Amount

Q7.9 * Currency

Q7.10 * Year

Q7.11 * Please specify scope of sub-national data (e.g. is this spending at the city level, regional level, etc?)

* Are sufficient funds available for programmes implemented by **government** in key areas of the HIV response?

	Yes	No	Don't know
Q7.12a Prevention	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q7.12b Testing	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q7.12c Treatment	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q7.12d Adherence and retention	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q7.12e Surveillance, monitoring and evaluation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

* Are sufficient funds available for programmes implemented by **civil society** in key areas of the HIV response?

	Yes	No	Don't know	N/A
Q7.13a Prevention	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q7.13b Testing	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q7.13c Treatment	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q7.13d Adherence and retention	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q7.14 Where are the most significant gaps in funding for HIV programmes?

PREVENTION SPENDING

* Over the past two years, has spending on HIV prevention for key populations increased, decreased or stayed approximately the same?

	Increased	Decreased	Same	No data
Q7.15a 2016	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q7.15b 2017	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q7.16 * Are sufficient funds available for HIV prevention to decrease the number of new infections in your country?

Yes

No

Don't know

Q7.17 * Do you have data on the estimated percentage of all funds (national and sub-national) allocated for HIV testing that are spent on programmes for key populations?

Yes

No

Go to Q7.20a

Q7.18 * What is the estimated percentage of all funds (national and sub-national) allocated for HIV prevention that are spent on programmes for key populations? (%)

Q7.19 * Which year does this figure relate to?

TESTING SPENDING

* Over the past two years, has spending on HIV testing for key populations increased, decreased or stayed approximately the same?

	Increased	Decreased	Same	No data
Q7.20a 2016	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q7.20b 2017	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Q7.21 * Are sufficient funds available for HIV testing to decrease the number of new infections in your country?		Yes No Don't know		<input type="radio"/> <input type="radio"/> <input type="radio"/>
Q7.22 * Do you have data on the estimated percentage of all funds (national and sub-national) allocated for HIV testing that are spent on programmes for key populations?		Yes No		<input type="radio"/> <input type="radio"/> Go to Q7.25
Q7.23 * What is the estimated percentage of all funds (national and sub-national) allocated for HIV testing that are spent on programmes for key populations? (%)		<input type="text"/>		
Q7.24 * Which year does this figure relate to?		<input type="text"/>		

TREATMENT SPENDING

Q7.25 What is the mean cost per patient per year of first line ART in your country?

Q7.26 In which currency is this cost provided?

Q7.27 Which year does this figure relate to?

Q7.28 What is the mean cost of oral PrEP per patient per year?¹⁴

14 Only relevant if PrEP is procured by the government in your country.

Q7.29 In which currency is this cost provided?

Q7.30 Which year does this figure relate to?

REVIEW

Please review your answers here. Please make any required changes by going back to the survey.

[\[All answers inserted here\]](#)

If you have fully completed and reviewed this section, please considering printing this page for your records.

For each section, you will be asked on the final page if you would like to attach any documents to your completed section. Please click the icons below to upload your file(s). When it has uploaded successfully, a unique ID will appear in the box.

Q7.31 Document 1:

Q7.32 To which question and answer does this document relate?

Q7.33 Document 2:

Q7.34 To which question and answer does this document relate?

Q7.35 Document 3:

Q7.36 To which question and answer does this document relate?

Q7.37 Document 4:

Q7.38 To which question and answer does this document relate?

Q7.39 Document 5:

Q7.40 To which question and answer does this document relate?

If you have fully completed and reviewed this section, please click on the SUBMIT button below. Please note that you will not be able to return to review your answers again once you have click SUBMIT.